|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...19202122232425262728293031 |
- |||||||||| New P3 trial: Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu (clinicaltrials.gov) - Oct 5, 2011
P3, N=244, Recruiting, Sponsor: Novartis
- FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: Cigarette Smoke and Susceptibility to Influenza Infection (clinicaltrials.gov) - Oct 4, 2011
P=N/A, N=135, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed
- ||| Foclivia (adjuvanted egg-based influenza A (H5N1) vaccine) / CSL Behring
Trial completion: Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine (clinicaltrials.gov) - Oct 3, 2011
P=N/A, N=7284, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine (clinicaltrials.gov) - Oct 2, 2011
P=N/A, N=4028, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | paracetamol / Generic mfg.
Trial completion: A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies (clinicaltrials.gov) - Sep 29, 2011
P4, N=28, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Completed
- FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Clinical: Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth (clinicaltrials.gov) - Sep 28, 2011
P=N/A, N=149, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- New P1 trial: Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Sep 28, 2011
P1, N=70, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Hutterite Influenza Prevention Study (clinicaltrials.gov) - Sep 26, 2011
P4, N=4771, Completed, Sponsor: McMaster University
Not yet recruiting --> Completed Recruiting --> Completed
- Enrollment change: Immune Responses Induced by Different Licensed Influenza Vaccines (clinicaltrials.gov) - Sep 25, 2011
P=N/A, N=36, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Recruiting --> Completed N=61 --> 36
- |||||||||| FluLaval Quadrivalent (influenza vaccine) / GSK
New P3 trial: A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older (clinicaltrials.gov) - Sep 22, 2011
P3, N=112, Completed, Sponsor: GlaxoSmithKline
- |||| Trial completion: Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) (clinicaltrials.gov) - Sep 22, 2011
P1/2, N=110, Completed, Sponsor: Baxter Healthcare Corporation
N=61 --> 36 Active, not recruiting --> Completed
- |||||||||| Fluarix Quadrivalent (influenza vaccine) / GSK
New P3 trial: An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (clinicaltrials.gov) - Sep 21, 2011
P3, N=12000, Recruiting, Sponsor: GlaxoSmithKline
- ||||| ASP7373 / Shionogi
New P2 trial: A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers (clinicaltrials.gov) - Sep 21, 2011
P2, N=180, Completed, Sponsor: Astellas Pharma Inc
- ||| Trial completion: Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=4529, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| MenHibrix (GSK 792014) / GSK
Trial completion: Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB (clinicaltrials.gov) - Sep 21, 2011
P3, N=270, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old (clinicaltrials.gov) - Sep 21, 2011
P1, N=521, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P2 trial: TIV and High Dose TIV in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 15, 2011
P2, N=102, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||||||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Trial completion: Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B (clinicaltrials.gov) - Sep 14, 2011
P3, N=131, Completed, Sponsor: Crucell Holland BV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Cell-mediated Immune Response to Influenza Vaccine (clinicaltrials.gov) - Sep 12, 2011
P1, N=100, Completed, Sponsor: University of Alberta
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects (clinicaltrials.gov) - Sep 12, 2011
P2/3, N=200, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P4 trial: Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults (clinicaltrials.gov) - Sep 6, 2011
P4, N=300, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- Clinical: Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions (clinicaltrials.gov) - Sep 5, 2011
P=N/A, N=3618, Completed, Sponsor: University of Michigan
- || New P3 trial: Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children (clinicaltrials.gov) - Sep 1, 2011
P3, N=2394, Completed, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
- |||| Trial completion: Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons (clinicaltrials.gov) - Aug 31, 2011
P4, N=121, Completed, Sponsor: Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Relenza (zanamivir) / GSK, Vaxart
Trial completion: Stop-Flu-2: Zanamivir Versus Trivalent Split Virus Influenza Vaccine (clinicaltrials.gov) - Aug 31, 2011
P3, N=64, Completed, Sponsor: Mount Sinai Hospital, Canada
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Study to Evaluate Impact of School-based Influenza Vaccination on School Populations (clinicaltrials.gov) - Aug 30, 2011
P=N/A, N=4500, Completed, Sponsor: Children's Hospital Los Angeles
Active, not recruiting --> Completed N=8000 --> 4500
- ||||| Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P4 trial: A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults (clinicaltrials.gov) - Aug 30, 2011
P4, N=31989, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- Trial completion: Study to Evaluate Impact of School-based Influenza Vaccination on School Populations (clinicaltrials.gov) - Aug 29, 2011
P=N/A, N=4500, Completed, Sponsor: Children's Hospital Los Angeles
N=8000 --> 4500 Recruiting --> Completed
- |||||||||| New P3 trial, Preclinical: Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects (clinicaltrials.gov) - Aug 22, 2011
P3, N=126, Completed, Sponsor: Novartis Vaccines
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: Direct and Indirect Benefits of Influenza Vaccination in Schools and Households (clinicaltrials.gov) - Aug 17, 2011
P4, N=6300, Completed, Sponsor: The University of Hong Kong
Recruiting --> Completed Recruiting --> Completed
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children (clinicaltrials.gov) - Aug 17, 2011
P=N/A, N=2800, Completed, Sponsor: The University of Hong Kong
Recruiting --> Completed Recruiting --> Completed
- ||||| universal flu vaccine (M-001) / Scinai Immunotherap
New P2 trial: A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers (clinicaltrials.gov) - Aug 16, 2011
P2, N=120, Recruiting, Sponsor: BiondVax Pharmaceuticals ltd.
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial termination: Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older (clinicaltrials.gov) - Aug 11, 2011
P3, N=9172, Terminated, Sponsor: Sanofi
Recruiting --> Completed Active, not recruiting --> Terminated; No safety concerns, study terminated due to lack of primary endpoint cases in 2009-2010 Flu season (coincided with H1N1 Pandemic) Subjects followed per-protocol
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment change: Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older (clinicaltrials.gov) - Aug 11, 2011
P3, N=9172, Terminated, Sponsor: Sanofi
Active, not recruiting --> Terminated; No safety concerns, study terminated due to lack of primary endpoint cases in 2009-2010 Flu season (coincided with H1N1 Pandemic) Subjects followed per-protocol N=33000 --> 9172
- | New P2 trial: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults (clinicaltrials.gov) - Aug 11, 2011
P2, N=78, Completed, Sponsor: GlaxoSmithKline
- ||| Trial completion: Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S. (clinicaltrials.gov) - Aug 11, 2011
P=N/A, N=180, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=33000 --> 9172 Active, not recruiting --> Completed
- |||| Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age (clinicaltrials.gov) - Aug 11, 2011
P2, N=300, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=28, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=100 --> 28
- Trial completion: Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=28, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=100 --> 28 Terminated --> Completed
- ||||||| FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age (clinicaltrials.gov) - Aug 10, 2011
P2/3, N=1800, Completed, Sponsor: MedImmune LLC
Terminated --> Completed Active, not recruiting --> Completed
- Enrollment change: Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine (clinicaltrials.gov) - Aug 10, 2011
P1, N=37, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=117 --> 37
- Fluzone (influenza vaccine) / Sanofi
Enrollment change: Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age (clinicaltrials.gov) - Aug 10, 2011
P1, N=23, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=117 --> 37 N=50 --> 23
- |||| Trial completion: A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age (clinicaltrials.gov) - Aug 9, 2011
P4, N=326, Completed, Sponsor: MedImmune LLC
N=50 --> 23 Active, not recruiting --> Completed
- |||| Fluzone (influenza vaccine) / Sanofi
Trial completion: Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM (clinicaltrials.gov) - Aug 9, 2011
P2, N=1250, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=0, Terminated, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed Recruiting --> Terminated; enrollment problems
- Enrollment change: Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=0, Terminated, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Terminated; enrollment problems N=30 --> 0
- |||||||||| New P3 trial: Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers (clinicaltrials.gov) - Aug 7, 2011
P3, N=440, Completed, Sponsor: Crucell Holland BV